Latest filing published 08 Mar 2023 for Arcutis Biotherapeutics, Inc., €12k.
Filing timeline
BuySaleInsider track record
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Kenneth A. Lock: trading record in brief
Kenneth A. Lock, listed as senior executive, appears in our data through filings on Arcutis Biotherapeutics, Inc. shares, published by SEC (Form 4). Between 27 February 2020 and 6 March 2023, the trades on record add up to 15 filings.
On the market, this insider has only sold: 8 sales, €104k in total. The rest of the record consists of 4 share grants and 3 option exercises. Since January 2023: no purchases and 4 sales on the market.
On 8 March 2023 came the latest disclosure, an open-market sale for €12k in Arcutis Biotherapeutics, Inc. Typically, a trade is published a median of 2 days after it takes place. Section 16 rules allow two business days to file each Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to Kenneth A. Lock
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 831 shares@ US$15.263629.1% of flowCommon StockSEC:0001567619-23-004667:0
- 21,000 shares0Common StockSEC:0001567619-23-004546:0
- 936 shares@ US$16.166334.8% of flowCommon StockSEC:0001567619-23-004269:0
- 13,300 shares0Common StockSEC:0001567619-22-006495:0
- 935 shares@ US$17.752736.1% of flowCommon StockSEC:0001567619-22-006226:0
5 of 5 declarations
